← All trials
NCT06043440
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 27, 2023
- Primary completion
- Aug 31, 2027
- Completion date
- Dec 27, 2027
- First posted
- Sep 21, 2023
- Last posted
- Sep 26, 2023
- Enrollment
- 230
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- University of PennsylvaniaCollaborator
- Case Western Reserve UniversityCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- University of WashingtonCollaborator
- University of MichiganCollaborator
- University of Southern CaliforniaCollaborator
- Old Dominion UniversityCollaborator
- University of CincinnatiCollaborator
- University of CincinnatiOverall official - principal investigator
- Children's Hospital Los AngelesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.